Signal_NN
transduction_NN
abnormalities_NNS
in_IN
T_NN
lymphocytes_NNS
from_IN
patients_NNS
with_IN
advanced_JJ
renal_JJ
carcinoma_NN
:_:
clinical_JJ
relevance_NN
and_CC
effects_NNS
of_IN
cytokine_NN
therapy_NN
._.

Studies_NNS
have_VBP
demonstrated_VBN
abnormalities_NNS
of_IN
the_DT
CD3\/T-cell_NN
antigen_NN
receptor_NN
-LRB-_-LRB-
TCR_NN
-RRB-_-RRB-
and_CC
pathways_NNS
of_IN
signal_NN
transduction_NN
in_IN
T_NN
lymphocytes_NNS
from_IN
animals_NNS
and_CC
patients_NNS
with_IN
advanced_JJ
malignancy_NN
._.

Diminished_VBN
expression_NN
of_IN
TCRzeta_NN
and_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
that_WDT
are_VBP
associated_VBN
with_IN
the_DT
TCR_NN
and_CC
reduced_VBD
nuclear_JJ
localization_NN
of_IN
RelA_NN
containing_VBG
nuclear_JJ
factor_NN
kappaB_NN
-LRB-_-LRB-
NFkappaB_NN
-RRB-_-RRB-
complexes_NNS
have_VBP
been_VBN
noted_VBN
._.

These_DT
defects_NNS
have_VBP
been_VBN
described_VBN
in_IN
T_NN
cells_NNS
from_IN
patients_NNS
with_IN
malignant_JJ
melanoma_NN
,_,
renal_JJ
cell_NN
carcinoma_NN
-LRB-_-LRB-
RCC_NN
-RRB-_-RRB-
,_,
ovarian_JJ
cancer_NN
,_,
and_CC
colorectal_JJ
cancer_NN
._.

Preliminary_JJ
observations_NNS
also_RB
indicate_VBP
possible_JJ
correlation_NN
with_IN
clinical_JJ
variables_NNS
such_JJ
as_IN
stage_NN
in_IN
selected_VBN
instances_NNS
._.

To_TO
further_RB
characterize_VB
altered_JJ
expression_NN
of_IN
TCRzeta_NN
,_,
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
,_,
and_CC
impaired_JJ
activation_NN
of_IN
NFkappaB_NN
,_,
T_NN
lymphocytes_NNS
were_VBD
obtained_VBN
from_IN
65_CD
patients_NNS
with_IN
RCC_NN
,_,
the_DT
majority_NN
of_IN
whom_WP
were_VBD
receiving_VBG
combination_NN
cytokine_NN
therapy_NN
-LCB-_-LRB-
interleukin_NN
-LRB-_-LRB-
IL_NN
-RRB-_-RRB-
-2_CD
,_,
IFN_NN
alpha-containing_JJ
regimens_NNS
-RCB-_-RRB-
and_CC
37_CD
control_JJ
individuals_NNS
._.

In_IN
29_CD
of_IN
these_DT
patients_NNS
,_,
levels_NNS
of_IN
TCRzeta_NN
and_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
were_VBD
determined_VBN
by_IN
Western_NN
blots_NNS
of_IN
T-cell_NN
lysates_NNS
and_CC
semiquantitated_VBN
using_VBG
densitometry_NN
._.

Relative_JJ
levels_NNS
were_VBD
then_RB
correlated_VBN
with_IN
a_DT
series_NN
of_IN
clinical_JJ
variables_NNS
including_VBG
response_NN
to_TO
therapy_NN
,_,
performance_NN
status_NN
,_,
survival_NN
,_,
disease_NN
sites_NNS
,_,
age_NN
,_,
and_CC
others_NNS
._.

In_IN
another_DT
group_NN
of_IN
28_CD
patients_NNS
-LRB-_-LRB-
three_CD
individuals_NNS
from_IN
the_DT
first_JJ
group_NN
-RRB-_-RRB-
,_,
the_DT
frequency_NN
of_IN
abnormal_JJ
NFkappaB_NN
activation_NN
was_VBD
studied_VBN
using_VBG
electrophoretic_JJ
mobility_NN
shift_NN
assays_NNS
after_IN
activation_NN
of_IN
T_NN
cells_NNS
with_IN
phorbol_NN
myristate_NN
acetate\/ionomycin_NN
or_CC
anti-CD3_JJ
monoclonal_JJ
antibody_NN
._.

Changes_NNS
in_IN
these_DT
signaling_NN
molecules_NNS
during_IN
cytokine_NN
treatment_NN
were_VBD
also_RB
investigated_VBN
._.

TCRzeta_NN
and_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
were_VBD
detected_VBN
in_IN
the_DT
peripheral_JJ
blood_NN
T_NN
cells_NNS
in_IN
27_CD
of_IN
29_CD
patients_NNS
,_,
and_CC
overall_RB
,_,
reduced_VBN
levels_NNS
were_VBD
noted_VBN
visually_RB
in_IN
12_CD
of_IN
29_CD
-LRB-_-LRB-
41_CD
%_NN
-RRB-_-RRB-
and_CC
13_CD
of_IN
29_CD
-LRB-_-LRB-
45_CD
%_NN
-RRB-_-RRB-
individuals_NNS
,_,
respectively_RB
._.

When_WRB
levels_NNS
were_VBD
semiquantitated_VBN
using_VBG
densitometry_NN
,_,
significant_JJ
decreases_NNS
of_IN
TCRzeta_NN
-LRB-_-LRB-
P_NN
=_JJ
0.029_CD
-RRB-_-RRB-
and_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
-LRB-_-LRB-
P_NN
=_JJ
0.029_CD
-RRB-_-RRB-
but_CC
not_RB
CD3epsilon_NN
-LRB-_-LRB-
P_NN
=_JJ
0.131_CD
-RRB-_-RRB-
,_,
compared_VBN
with_IN
control_NN
levels_NNS
,_,
were_VBD
found_VBN
._.

In_IN
patients_NNS
treated_VBN
with_IN
IL-2_NN
\/_:
IFN_NN
alpha-based_JJ
therapy_NN
,_,
relative_JJ
levels_NNS
of_IN
TCRzeta_NN
increased_VBD
significantly_RB
-LRB-_-LRB-
P_NN
=_JJ
0.002_CD
-RRB-_-RRB-
on_IN
day_NN
15_CD
of_IN
cycle_NN
one_CD
compared_VBN
with_IN
the_DT
baseline_NN
._.

Correlations_NNS
of_IN
TCRzeta_NN
or_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
levels_NNS
with_IN
response_NN
or_CC
disease_NN
variables_NNS
,_,
except_VBN
for_IN
lower_JJR
TCRzeta_NN
levels_NNS
-LRB-_-LRB-
P_NN
&lt;_JJR
0.001_CD
-RRB-_-RRB-
in_IN
the_DT
presence_NN
of_IN
bone_NN
metastases_NNS
,_,
were_VBD
not_RB
found_VBN
._.

Abnormal_JJ
NFkappaB_NN
activation_NN
after_IN
stimulation_NN
with_IN
phorbol_NN
myristate_NN
acetate\/ionomycin_NN
and\/or_CC
anti-CD3_JJ
monoclonal_JJ
antibody_NN
was_VBD
found_VBN
in_IN
59_CD
%_NN
of_IN
patients_NNS
-LRB-_-LRB-
17_CD
of_IN
28_CD
-RRB-_-RRB-
and_CC
was_VBD
not_RB
accounted_VBN
for_IN
by_IN
the_DT
advanced_JJ
age_NN
of_IN
the_DT
study_NN
cohort_NN
._.

Activation_NN
of_IN
NFkappaB_NN
in_IN
peripheral_JJ
blood_NN
T_NN
cells_NNS
was_VBD
inducible_JJ
during_IN
cytokine_NN
therapy_NN
in_IN
four_CD
of_IN
six_CD
individuals_NNS
who_WP
displayed_VBD
impaired_JJ
NFkappaB_NN
activity_NN
prior_JJ
to_TO
therapy_NN
._.

Moreover_RB
,_,
impaired_JJ
activation_NN
of_IN
NFkappaB_NN
does_VBZ
not_RB
appear_VB
linked_VBN
to_TO
a_DT
reduction_NN
of_IN
TCRzeta_NN
expression_NN
,_,
because_IN
in_IN
five_CD
patients_NNS
,_,
normal_JJ
TCRzeta_NN
levels_NNS
were_VBD
present_JJ
although_IN
kappaB_NN
binding_NN
was_VBD
not_RB
inducible_JJ
._.

In_IN
the_DT
majority_NN
of_IN
patients_NNS
with_IN
advanced_JJ
RCC_NN
,_,
peripheral_JJ
blood_NN
T_NN
cells_NNS
express_VBP
TCRzeta_NN
and_CC
p56_NN
-LRB-_-LRB-
lck_NN
-RRB-_-RRB-
,_,
and_CC
in_IN
a_DT
subset_NN
,_,
reduced_VBN
levels_NNS
of_IN
these_DT
TCRzeta_NN
associated_JJ
molecules_NNS
are_VBP
seen_VBN
that_IN
may_MD
increase_VB
during_IN
cytokine-based_JJ
therapy_NN
._.

Abnormal_JJ
activation_NN
of_IN
NFkappaB_NN
is_VBZ
also_RB
present_JJ
in_IN
&gt;_JJR
50_CD
%_NN
of_IN
patients_NNS
and_CC
may_MD
also_RB
revert_VB
to_TO
normal_JJ
during_IN
IL-2_NN
\/_:
IFN_NN
alpha-based_JJ
treatment_NN
._.

This_DT
alteration_NN
in_IN
NFkappaB_NN
activation_NN
occurred_VBD
in_IN
the_DT
presence_NN
of_IN
normal_JJ
expression_NN
of_IN
TCRzeta-associated_JJ
signaling_NN
elements_NNS
._.

The_DT
clinical_JJ
significance_NN
of_IN
these_DT
findings_NNS
remains_VBZ
unclear_JJ
._.

